ALABAMA PUBLIC HEALTH

ALABAMA STD REPORTS QUARTERLY SURVEILLANCE REPORT DIVISION OF STD, BUREAU OF COMMUNICABLE DISEASE

Division of STD, Bureau of Communicable Disease • Alabama Department of Public Health 201 Monroe Street, Suite 1440, Montgomery, Alabama 36104 • (334) 206–5350

VOL. 2016, NO. 2

DR. MILLER'S MESSAGE

'TALK, TEST, AND TREAT' TO PREVENT SEXUALLY TRANSMITTED DISEASE (STDS) AND THEIR PROGRESSION

April is STD Awareness Month, an annual observance to call attention to the impact of STDs and promote STD testing across the nation. This year's theme, which was selected by the Centers for Disease Control and Prevention (CDC), is "Talk, Test, and Treat." This month-long observance provides an opportunity to correct misperceptions about STD prevention and testing, and confront the unique challenges that young people face when it comes to preventing these infections. Because half of the estimated 20 million STDs that occur in the United States each year are among young people, STD Awareness Month 2016 focuses on this population.

According to the CDC, cases of syphilis and other STDs have increased for the first time since 2006, which has led to the need for better diagnosis, treatment, and prevention. STDs remain a problem in Alabama, and their health consequences can last a lifetime. Of particular concern in Alabama are recent increases in primary and secondary syphilis; these are the earliest and most transmissible stages of syphilis. In 2016, the number of syphilis cases in these two stages reported to the Alabama Department of Public Health increased by 68.3 percent (276 cases) compared to the number of cases (164) reported in 2014.


Home remedies or over-the-counter drugs will not cure syphilis; however, syphilis is easy to cure in its early stages with the correct antibiotics. Treatment will not reverse any damage the infection has already caused, so it is very important to get early treatment from a health care provider. If left untreated, syphilis can have very serious complications. Please check this website http://adph.org/std/ for information about the signs and symptoms of syphilis.

The simple recommendations below will help protect sexual health by minimizing the negative and sometimes lifelong consequences of these infections:

TALK

Talk openly and honestly to your partner(s) and your health care provider about sexual health and STDs. Talk with your partner before having sex, and make sure your discussion covers several important ways to make sex safer:

• Talk about when you were last tested and suggest being tested together. If you have an STD (like herpes or HIV), tell your partner.



- Agree to maintain monogamous sexual relationships.
- Use latex condoms the right way every time you have sex.
- Talk with your health care provider about your sex life, and ask what STD tests you should be getting and how often.

Not all medical checkups include STD testing, so unless you discuss whether you are being tested, do not assume that you have been. Vaccines for Hepatitis B and Human papillomavirus (HPV) are available.

Test

Many STDs have no symptoms, so get tested to be certain you do not have an STD. If you are having sex, getting tested is one of the most important actions you can take to protect your health.

Find out which STD tests CDC recommends and remember, pregnancy does not protect against STDs. If you are having sex, you are still at risk. If you are not comfortable talking with your regular health care provider about STDs, find a clinic near you that provides confidential and free or low-cost testing.

тгеат

If you test positive for an STD, work with your health care provider to get the correct treatment. Some STDs can be cured with the right medicine, and it is important that you take all of the prescribed medication. To make sure your treatment is effective:

- · Do not share your medicine with anyone, and
- Avoid having sex again until you and your sex partner(s) have each completed treatment.
- Other STDs are not curable, but they are treatable. Your health care provider can talk with you about which medications are right for you.

We encourage sexually active people to get themselves tested to control STDs. Free testing and treatment is provided for syphilis, chlamydia, gonorrhea, and HIV at county health departments.

The mission of the Alabama Department of Public Health Division of STD Prevention and Control is to identify populations at increased risk for infection in order to reduce their chances of developing a sexually transmitted disease, transmitting it to others, and developing related complications. Trained public health staff statewide provide screening, diagnostic, education, treatment, partner notification, and referral services in all Alabama counties. These public health staff members include registered nurses, nurse practitioners, physicians, and disease intervention specialists. Keep in mind that all services are confidential.

ALABAMA DEPARTMENT OF PUBLIC HEALTH • DIVISION OF STD

The Alabama STD Report: Vol. 2016, No. 3 represents preliminary statistics and trends of sexually transmitted diseases in Alabama from January 1 through March 31, 2016. All reports are presented by date of diagnosis. This report is intended as a reference document for local health departments, program managers, health care providers. community based organization, state legislators, researchers and others who are concerned with the public health implications of these diseases. The information in this quarterly report is meant to be brief and provide limited data on these diseases throughout the year. More detailed and complete information will continue to be available in annual publications. This report and our annual publications will be available on our website (http://adph.org/std). National data about these diseases is available on the Centers for Disease Control and Prevention's website (http://cdc.gov).

CHLAMYDIA SURVEILLANCE DATA

Chlamydia case reports represent persons who have a positive laboratory test for chlamydia. It is important to note that chlamydial infection is often asymptomatic in females and males. Most cases are detected through screening. The disease can cause serious complications in females including pelvic inflammatory disease. Asymptomatic infection is common among both men and women. Annual screening of all sexually active women ≤ 25 years of age is recommended. as is screening of older women with risk factors (e.g., those who have a new sex partner or multiple sex partners). Screening programs have been demonstrated to reduce both the prevalence of C. trachomatis infection and rates of pelvic inflammatory disease (PID) in women. The screening of sexually active young men should be considered in clinical settings with a high prevalence of chlamydia (e.g., adolescent clinics, correctional facilities and STD clinics).

GONORRHEA SURVEILLANCE DATA

Gonorrhea case reports represent persons who have a positive laboratory test for gonorrhea. The majority of urethral infections caused by N. gonorrhoeae among men produce symptoms that cause them to seek curative treatment sooner to prevent serious sequelae, but treatment might not be soon enough to prevent transmission to others. Among women, gonoccocal infections might not produce recognizable symptoms until complications (e.g., PID) have occurred. PID can results in tubal scarring that lead to infertility or ectopic pregnancy.

HIV AND AIDS SURVEILLANCE DATA

HIV case reports represent persons who have a confirmed diagnosis with human immunodeficiency virus (HIV) only. This represents all new diagnosis of HIV in Alabama regardless of the stage of the disease. Most persons are reported with only HIV infection, but some are reported with a concurrent diagnosis of AIDS (acquired immunodeficiency syndrome). HIV Stage 3 (AIDS) case reports represent persons with HIV infection who have progressed to AIDS. HIV infection and AIDS cases are presented in this report by date of diagnosis.

SYPHILIS SURVEILLANCE DATA

Syphilis reports are reported by stage of infection which is determined through a combination of laboratory testing, patient examination and interviews. Primary and secondary syphilis have specific signs and symptoms associated with them. Early latent syphilis is asymptomatic but can be staged with confirmation that the infection is less than a year old. Primary, secondary and early syphilis cases comprise "early syphilis" cases. Alabama conducts interviews on all early syphilis cases.

TRICHOMONIASIS SURVEILLANCE DATA

Trichomoniasis case reports represent persons who have a laboratory confirmed case of trichomoniasis infection. It is the most curable sexually transmitted disease. Trichomoniasis is often asymptomatic in females and males. The infection is more common in women than in men, and older women are more likely than younger women to be infected. Untreated trichomoniasis infection can increase the risk of HIV infection in men and women.

CENTER FO	R DISEASE CONTROL AND PREVENTION TREATMENT GUIDELINES
Chlamydia:	Azithromycin 1 g PO in a single dose or Doxycycline 100 mg PO twice a day for 7 days
Gonorrhea:	Ceftriaxone 250 mg IM in a single dose PLUS Azithromycin 1 g PO in a single dose
	or Ceftriaxone 250 mg IM in a single dose PLUS Doxycycline 100 mg PO twice a day for 7 days
	If Ceftriaxone is not available: Cefixime 400mg orally in a single dose PLUS Azithromycin 1 g
	PO in a single dose
Syphilis:	Early Syphilis – Bicillin 2.4 MU IM in a single dose
	Late Syphilis – Bicillin 2.4 MU IM weekly for three consecutive weeks
	Neuro Syphilis – Aqueous crystalline penicillin G 18-24 MU per day, divided into 3-4 MU IV every
	4 hours or continuous infusion for 10-14 days
Trichomoniasis:	Metronidazole 2 g PO in a single dose or Tinidazole 2 g PO in a single dose
CDC Treatment C	Guidelines: http://www.cdc.gov/std/tg2016/toc.htm

2016 Chlan	2016 Chlamydia Report		Qtr	2 nd	Qtr	3 rd	Qtr	4 th	Qtr	Year to Date	
Sex	Age Group	Cases	%	Cases	%	Cases	%	Cases	%	Cases	%
	0-9	1	0.05	N/A	N/A	N/A	N/A	N/A	N/A	1	0.05
	10-14	4	0.21	N/A	N/A	N/A	N/A	N/A	N/A	4	0.21
	15-19	371	19.38	N/A	N/A	N/A	N/A	N/A	N/A	371	19.38
	20-24	805	42.06	N/A	N/A	N/A	N/A	N/A	N/A	805	42.06
	25-29	399	20.85	N/A	N/A	N/A	N/A	N/A	N/A	399	20.85
Mala	30-34	173	9.04	N/A	N/A	N/A	N/A	N/A	N/A	173	9.04
Male	35-39	73	3.81	N/A	N/A	N/A	N/A	N/A	N/A	73	3.81
	40-44	35	1.83	N/A	N/A	N/A	N/A	N/A	N/A	35	1.83
	45-54	39	2.04	N/A	N/A	N/A	N/A	N/A	N/A	39	2.04
	55-64	12	0.63	N/A	N/A	N/A	N/A	N/A	N/A	12	0.63
	65+	2	0.10	N/A	N/A	N/A	N/A	N/A	N/A	2	0.10
	Total	1914	100.00	N/A	N/A	N/A	N/A	N/A	N/A	1914	100.00
	0-9	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	10-14	35	0.79	N/A	N/A	N/A	N/A	N/A	N/A	35	0.79
	15-19	1490	33.57	N/A	N/A	N/A	N/A	N/A	N/A	1490	33.57
	20-24	1845	41.56	N/A	N/A	N/A	N/A	N/A	N/A	1845	41.56
	25-29	666	15.00	N/A	N/A	N/A	N/A	N/A	N/A	666	15.00
Famala	30-34	231	5.20	N/A	N/A	N/A	N/A	N/A	N/A	231	5.20
Female	35-39	109	2.46	N/A	N/A	N/A	N/A	N/A	N/A	109	2.46
	40-44	35	0.79	N/A	N/A	N/A	N/A	N/A	N/A	35	0.79
	45-54	19	0.43	N/A	N/A	N/A	N/A	N/A	N/A	19	0.43
	55-64	7	0.16	N/A	N/A	N/A	N/A	N/A	N/A	7	0.16
	65+	2	0.05	N/A	N/A	N/A	N/A	N/A	N/A	2	0.05
	Total	4439	100.00	N/A	N/A	N/A	N/A	N/A	N/A	4439	100.00
	0-9	1	0.02	N/A	N/A	N/A	N/A	N/A	N/A	1	0.02
	10-14	39	0.61	N/A	N/A	N/A	N/A	N/A	N/A	39	0.61
	15-19	1882	29.40	N/A	N/A	N/A	N/A	N/A	N/A	1882	29.40
	20-24	2671	41.73	N/A	N/A	N/A	N/A	N/A	N/A	2671	41.73
	25-29	1069	16.70	N/A	N/A	N/A	N/A	N/A	N/A	1069	16.70
Total	30-34	406	6.34	N/A	N/A	N/A	N/A	N/A	N/A	406	6.34
Total	35-39	182	2.84	N/A	N/A	N/A	N/A	N/A	N/A	182	2.84
	40-44	70	1.09	N/A	N/A	N/A	N/A	N/A	N/A	70	1.09
	45-54	58	0.91	N/A	N/A	N/A	N/A	N/A	N/A	58	0.91
	55-64	19	0.30	N/A	N/A	N/A	N/A	N/A	N/A	19	0.30
	65+	4	0.06	N/A	N/A	N/A	N/A	N/A	N/A	4	0.06
	Total	6401	100.00	N/A	N/A	N/A	N/A	N/A	N/A	6401	100.00

2016 Gonor	2016 Gonorrhea Report		Qtr	2 nd	Qtr	3rd	Qtr	4 th	Qtr	Year to Date	
Sex	Age Group	Cases	%	Cases	%	Cases	%	Cases	%	Cases	%
	0-9	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	10-14	1	0.11	N/A	N/A	N/A	N/A	N/A	N/A	1	0.11
	15-19	125	13.37	N/A	N/A	N/A	N/A	N/A	N/A	125	13.37
	20-24	360	38.50	N/A	N/A	N/A	N/A	N/A	N/A	360	38.50
	25-29	196	21.00	N/A	N/A	N/A	N/A	N/A	N/A	196	21.00
Mala	30-34	97	10.37	N/A	N/A	N/A	N/A	N/A	N/A	97	10.37
Male	35-39	63	6.74	N/A	N/A	N/A	N/A	N/A	N/A	63	6.74
	40-44	40	4.28	N/A	N/A	N/A	N/A	N/A	N/A	40	4.28
	45-54	32	3.42	N/A	N/A	N/A	N/A	N/A	N/A	32	3.42
	55-64	15	1.60	N/A	N/A	N/A	N/A	N/A	N/A	15	1.60
	65+	6	0.64	N/A	N/A	N/A	N/A	N/A	N/A	6	0.64
	Total	935	100.00	N/A	N/A	N/A	N/A	N/A	N/A	935	100.00
	0-9	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	10-14	6	0.67	N/A	N/A	N/A	N/A	N/A	N/A	6	0.67
	15-19	248	27.90	N/A	N/A	N/A	N/A	N/A	N/A	248	27.90
	20-24	365	41.05	N/A	N/A	N/A	N/A	N/A	N/A	365	41.05
	25-29	151	16.99	N/A	N/A	N/A	N/A	N/A	N/A	151	16.99
Famala	30-34	59	6.64	N/A	N/A	N/A	N/A	N/A	N/A	59	6.64
Female	35-39	33	3.71	N/A	N/A	N/A	N/A	N/A	N/A	33	3.71
	40-44	13	1.46	N/A	N/A	N/A	N/A	N/A	N/A	13	1.46
	45-54	11	1.24	N/A	N/A	N/A	N/A	N/A	N/A	11	1.24
	55-64	2	0.22	N/A	N/A	N/A	N/A	N/A	N/A	2	0.22
	65+	1	0.11	N/A	N/A	N/A	N/A	N/A	N/A	1	0.11
	Total	889	100.00	N/A	N/A	N/A	N/A	N/A	N/A	889	100.00
	0-9	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	10-14	7	0.38	N/A	N/A	N/A	N/A	N/A	N/A	7	0.38
	15-19	380	20.72	N/A	N/A	N/A	N/A	N/A	N/A	380	20.72
	20-24	728	39.70	N/A	N/A	N/A	N/A	N/A	N/A	728	39.70
	25-29	347	18.92	N/A	N/A	N/A	N/A	N/A	N/A	347	18.92
Tatal	30-34	156	8.51	N/A	N/A	N/A	N/A	N/A	N/A	156	8.51
Total	35-39	96	5.23	N/A	N/A	N/A	N/A	N/A	N/A	96	5.23
	40-44	53	2.89	N/A	N/A	N/A	N/A	N/A	N/A	53	2.89
	45-54	43	2.34	N/A	N/A	N/A	N/A	N/A	N/A	43	2.34
	55-64	17	0.93	N/A	N/A	N/A	N/A	N/A	N/A	17	0.93
	65+	7	0.38	N/A	N/A	N/A	N/A	N/A	N/A	7	0.38
	Total	1834	100.00	N/A	N/A	N/A	N/A	N/A	N/A	1834	100.00

2016 Trichom	2016 Trichomoniasis Report		1 st Qtr		Qtr	3 rd	Qtr	4 th	Qtr	Year to Date	
Sex	Age Group	Cases	%	Cases	%	Cases	%	Cases	%	Cases	%
	0-9	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	10-14	1	0.28	N/A	N/A	N/A	N/A	N/A	N/A	1	0.28
	15-19	11	3.13	N/A	N/A	N/A	N/A	N/A	N/A	11	3.13
	20-24	78	22.22	N/A	N/A	N/A	N/A	N/A	N/A	78	22.22
	25-29	76	21.65	N/A	N/A	N/A	N/A	N/A	N/A	76	21.65
Mala	30-34	53	15.10	N/A	N/A	N/A	N/A	N/A	N/A	53	15.10
Male	35-39	37	10.54	N/A	N/A	N/A	N/A	N/A	N/A	37	10.54
	40-44	26	7.41	N/A	N/A	N/A	N/A	N/A	N/A	26	7.41
	45-54	30	8.55	N/A	N/A	N/A	N/A	N/A	N/A	30	8.55
	55-64	30	8.55	N/A	N/A	N/A	N/A	N/A	N/A	30	8.55
	65+	9	2.56	N/A	N/A	N/A	N/A	N/A	N/A	9	2.56
	Total	351	100.00	N/A	N/A	N/A	N/A	N/A	N/A	351	100.00
	0-9	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	10-14	9	0.34	N/A	N/A	N/A	N/A	N/A	N/A	9	0.34
	15-19	237	9.04	N/A	N/A	N/A	N/A	N/A	N/A	237	9.04
	20-24	732	27.92	N/A	N/A	N/A	N/A	N/A	N/A	732	27.92
	25-29	623	23.76	N/A	N/A	N/A	N/A	N/A	N/A	623	23.76
Formala	30-34	416	15.87	N/A	N/A	N/A	N/A	N/A	N/A	416	15.87
Female	35-39	259	9.88	N/A	N/A	N/A	N/A	N/A	N/A	259	9.88
	40-44	151	5.76	N/A	N/A	N/A	N/A	N/A	N/A	151	5.76
	45-54	155	5.91	N/A	N/A	N/A	N/A	N/A	N/A	155	5.91
	55-64	39	1.49	N/A	N/A	N/A	N/A	N/A	N/A	39	1.49
	65+	1	0.04	N/A	N/A	N/A	N/A	N/A	N/A	1	0.04
	Total	2622	100.00	N/A	N/A	N/A	N/A	N/A	N/A	2622	100.00
	0-9	1	0.03	N/A	N/A	N/A	N/A	N/A	N/A	1	0.03
	10-14	10	0.34	N/A	N/A	N/A	N/A	N/A	N/A	10	0.34
	15-19	254	8.51	N/A	N/A	N/A	N/A	N/A	N/A	254	8.51
	20-24	814	27.27	N/A	N/A	N/A	N/A	N/A	N/A	814	27.27
	25-29	699	23.42	N/A	N/A	N/A	N/A	N/A	N/A	699	23.42
Total	30-34	469	15.71	N/A	N/A	N/A	N/A	N/A	N/A	469	15.71
Total	35-39	296	9.92	N/A	N/A	N/A	N/A	N/A	N/A	296	9.92
	40-44	177	5.93	N/A	N/A	N/A	N/A	N/A	N/A	177	5.93
	45-54	185	6.20	N/A	N/A	N/A	N/A	N/A	N/A	185	6.20
	55-64	70	2.35	N/A	N/A	N/A	N/A	N/A	N/A	70	2.35
	65+	10	0.34	N/A	N/A	N/A	N/A	N/A	N/A	10	0.34
	Total	2985	100.00	N/A	N/A	N/A	N/A	N/A	N/A	2985	100.00

2016 P&S Sy	2016 P&S Syphilis Report		Qtr	2 nd	Qtr	3 rd	Qtr	4 th	Qtr	Year to Date	
Sex	Age Group	Cases	%	Cases	%	Cases	%	Cases	%	Cases	%
	0-9	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	10-14	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	15-19	3	6.00	N/A	N/A	N/A	N/A	N/A	N/A	3	6.00
	20-24	16	32.00	N/A	N/A	N/A	N/A	N/A	N/A	16	32.00
	25-29	15	30.00	N/A	N/A	N/A	N/A	N/A	N/A	15	30.00
Mala	30-34	7	14.00	N/A	N/A	N/A	N/A	N/A	N/A	7	14.00
Male	35-39	4	8.00	N/A	N/A	N/A	N/A	N/A	N/A	4	8.00
	40-44	2	4.00	N/A	N/A	N/A	N/A	N/A	N/A	2	4.00
	45-54	2	4.00	N/A	N/A	N/A	N/A	N/A	N/A	2	4.00
	55-64	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	65+	1	2.00	N/A	N/A	N/A	N/A	N/A	N/A	1	2.00
	Total	50	100.00	N/A	N/A	N/A	N/A	N/A	N/A	50	100.00
	0-9	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	10-14	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	15-19	4	21.05	N/A	N/A	N/A	N/A	N/A	N/A	4	21.05
	20-24	8	42.11	N/A	N/A	N/A	N/A	N/A	N/A	8	42.11
	25-29	3	15.79	N/A	N/A	N/A	N/A	N/A	N/A	3	15.79
Family	30-34	2	10.53	N/A	N/A	N/A	N/A	N/A	N/A	2	10.53
Female	35-39	1	5.26	N/A	N/A	N/A	N/A	N/A	N/A	1	5.26
	40-44	1	5.26	N/A	N/A	N/A	N/A	N/A	N/A	1	5.26
	45-54	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	55-64	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	65+	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	Total	19	100.00	N/A	N/A	N/A	N/A	N/A	N/A	19	100.00
	0-9	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	10-14	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	15-19	7	10.14	N/A	N/A	N/A	N/A	N/A	N/A	7	10.14
	20-24	24	34.78	N/A	N/A	N/A	N/A	N/A	N/A	24	34.78
	25-29	18	26.09	N/A	N/A	N/A	N/A	N/A	N/A	18	26.09
T-4-1	30-34	9	13.04	N/A	N/A	N/A	N/A	N/A	N/A	9	13.04
Total	35-39	5	7.25	N/A	N/A	N/A	N/A	N/A	N/A	5	7.25
	40-44	3	4.35	N/A	N/A	N/A	N/A	N/A	N/A	3	4.35
	45-54	2	2.90	N/A	N/A	N/A	N/A	N/A	N/A	2	2.90
	55-64	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	65+	1	1.45	N/A	N/A	N/A	N/A	N/A	N/A	1	1.45
	Total	69	100.00	N/A	N/A	N/A	N/A	N/A	N/A	69	100.00

2016 Early Latent Syphilis Report		1 st	Qtr	2 nd	Qtr	3 rd	Qtr	4 th	Qtr	Year to Date	
Sex	Age Group	Cases	%	Cases	%	Cases	%	Cases	%	Cases	%
	0-9	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	10-14	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	15-19	2	6.25	N/A	N/A	N/A	N/A	N/A	N/A	2	6.25
	20-24	10	31.25	N/A	N/A	N/A	N/A	N/A	N/A	10	31.25
	25-29	6	18.75	N/A	N/A	N/A	N/A	N/A	N/A	6	18.75
Mala	30-34	3	9.38	N/A	N/A	N/A	N/A	N/A	N/A	3	9.38
Male	35-39	1	3.13	N/A	N/A	N/A	N/A	N/A	N/A	1	3.13
	40-44	4	12.50	N/A	N/A	N/A	N/A	N/A	N/A	4	12.50
	45-54	5	15.63	N/A	N/A	N/A	N/A	N/A	N/A	5	15.63
	55-64	1	3.13	N/A	N/A	N/A	N/A	N/A	N/A	1	3.13
	65+	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	Total	32	100.00	N/A	N/A	N/A	N/A	N/A	N/A	32	100.00
	0-9	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	10-14	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	15-19	2	20.00	N/A	N/A	N/A	N/A	N/A	N/A	2	20.00
	20-24	4	40.00	N/A	N/A	N/A	N/A	N/A	N/A	4	40.00
	25-29	2	20.00	N/A	N/A	N/A	N/A	N/A	N/A	2	20.00
Famala	30-34	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
Female	35-39	1	10.00	N/A	N/A	N/A	N/A	N/A	N/A	1	10.00
	40-44	1	10.00	N/A	N/A	N/A	N/A	N/A	N/A	1	10.00
	45-54	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	55-64	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	65+	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	Total	10	100.00	N/A	N/A	N/A	N/A	N/A	N/A	10	100.00
	0-9	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	10-14	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	15-19	4	9.52	N/A	N/A	N/A	N/A	N/A	N/A	4	9.52
	20-24	14	33.33	N/A	N/A	N/A	N/A	N/A	N/A	14	33.33
	25-29	8	19.05	N/A	N/A	N/A	N/A	N/A	N/A	8	19.05
T . ()	30-34	3	7.14	N/A	N/A	N/A	N/A	N/A	N/A	3	7.14
Total	35-39	2	4.76	N/A	N/A	N/A	N/A	N/A	N/A	2	4.76
	40-44	5	11.09	N/A	N/A	N/A	N/A	N/A	N/A	5	11.09
	45-54	5	11.09	N/A	N/A	N/A	N/A	N/A	N/A	5	11.09
	55-64	1	2.38	N/A	N/A	N/A	N/A	N/A	N/A	1	2.38
	65+	0	0.00	N/A	N/A	N/A	N/A	N/A	N/A	0	0.00
	Total	42	100.00	N/A	N/A	N/A	N/A	N/A	N/A	42	100.00

	CHLAMYDIA			G	ONORRHE	A	TRICHOMONIASIS			
Year to Date	2014 Jan-Mar	2015 Jan-Mar	2016 Jan-Mar	2014 Jan-Mar	2015 Jan-Mar	2016 Jan-Mar	2014 Jan-Mar	2015 Jan-Mar	2016 Jan-Mar	
Autuaga	49	49	41	10	13	5	17	12	14	
Baldwin	149	180	169	41	35	40	16	16	17	
Barbour	52	33	37	18	8	15	36	29	39	
Bibb	19	14	22	7	6	6	11	9	10	
Blount	24	12	20	3	1	4	5	7	3	
Bullock	18	24	23	6	15	6	10	8	13	
Butler	40	55	33	10	13	9	16	33	22	
Calhoun	213	171	151	47	49	47	85	104	85	
Chambers	68	61	48	16	8	17	33	38	49	
Cherokee	15	6	17	3	9	3	11	7	11	
Chilton	26	26	39	8	5	11	11	14	19	
Choctaw	21	11	7	4	4	2	10	9	12	
Clarke	46	51	32	11	6	5	24	37	18	
Clay	10	10	5	2	6	0	6	9	5	
Cleburne	7	11	13	1	1	1	7	3	7	
Coffee	64	66	48	13	22	10	33	31	26	
Colbert	70	56	58	9	18	11	43	35	29	
Conecuh	18	22	13	0	0	2	18	11	7	
Coosa	12	12	7	0	3	0	4	2	12	
Covington	40	47	46	4	2	5	21	27	13	
Crenshaw	27	18	24	3	8	5	11	11	8	
Cullman	61	58	46	4	8	6	9	13	23	
Dale	75	76	67	13	21	19	42	34	47	
Dallas	87	107	128	10	21	21	61	80	72	
DeKalb	39	43	43	10	6	4	9	10	18	
Elmore	96	69	79	20	15	24	36	32	37	
Escambia	43	48	49	16	14	12	26	28	33	
Etowah	165	105	133	46	34	36	88	51	87	
Fayette	23	17	26	0	5	13	10	13	7	
Franklin	23	22	22	2	1	2	18	14	12	
Geneva	41	20	27	11	8	10	18	15	14	
Greene	33	19	32	10	6	4	21	22	16	
Hale	59	40	35	9	8	11	31	23	20	

Year to Date	C	HLAMYDI	Α	G	ONORRHE	A	TRIC	CHOMONIA	ASIS
Henry	14	19	12	6	2	5	15	15	18
Houston	210	162	131	56	39	44	165	139	101
Jackson	34	33	23	3	2	5	10	12	14
Jefferson	1219	1116	1239	361	400	495	573	607	660
Lamar	14	9	8	3	2	7	6	3	7
Lauderdale	104	108	86	11	17	9	53	42	39
Lawrence	31	13	18	1	2	4	18	20	10
Lee	189	212	218	32	64	65	71	52	44
Limestone	63	43	55	24	17	11	40	37	28
Lowndes	28	35	22	10	3	7	14	8	21
Macon	73	51	47	14	8	12	22	14	23
Madison	473	455	424	176	150	200	110	134	127
Marengo	44	36	29	5	10	7	15	18	18
Marion	20	16	14	2	4	6	7	14	13
Marshall	51	37	44	6	13	11	16	14	12
Mobile	756	717	702	174	143	110	343	312	289
Monroe	35	18	19	6	5	2	21	19	13
Montgomery	706	646	476	274	182	117	237	227	170
Morgan	100	84	102	17	18	24	71	54	58
Perry	21	22	17	3	1	8	14	19	16
Pickens	33	33	25	7	3	9	18	23	17
Pike	83	67	83	30	18	24	39	40	41
Randolph	21	25	24	3	1	2	19	14	20
Russell	98	83	111	24	29	30	50	39	47
Shelby	84	103	84	18	24	20	24	41	31
St Clair	46	37	52	15	22	29	25	26	21
Sumter	43	33	40	5	4	10	28	21	20
Talladega	125	108	117	38	36	40	79	80	72
Tallapoosa	49	45	57	9	12	15	44	29	36
Tuscaloosa	360	320	454	62	78	108	151	128	125
Walker	78	60	58	10	20	21	32	32	34
Washington	14	20	19	6	5	3	10	9	8
Wilcox	26	24	26	3	2	4	17	25	26
Winston	16	14	13	0	0	1	6	5	5
Total	7002	6369	6401	1787	1716	1834	3162	3065	2985

	P	SS SYPHIL	IS	EARLY	LATENT S	YPHILIS	OTH	IER SYPH	ILIS
Year to Date	2014 Jan-Mar	2015 Jan-Mar	2016 Jan-Mar	2014 Jan-Mar	2015 Jan-Mar	2016 Jan-Mar	2014 Jan-Mar	2015 Jan-Mar	2016 Jan-Mar
Autuaga	0	0	1	0	1	0	0	0	0
Baldwin	2	2	1	0	1	0	0	2	1
Barbour	1	0	0	0	0	0	1	0	1
Bibb	0	0	0	0	0	0	0	0	0
Blount	0	0	0	0	0	0	0	0	0
Bullock	0	0	0	0	0	0	0	0	0
Butler	0	0	0	0	0	0	0	0	0
Calhoun	1	0	0	0	3	0	1	2	0
Chambers	0	0	0	0	0	2	1	0	0
Cherokee	0	0	0	0	0	1	0	0	0
Chilton	0	0	0	0	0	0	0	1	0
Choctaw	0	0	0	0	0	0	0	0	0
Clarke	0	1	0	0	0	0	0	0	0
Clay	0	0	0	0	0	0	0	0	0
Cleburne	0	0	0	1	0	0	0	0	0
Coffee	0	1	0	0	0	1	0	0	0
Colbert	1	1	0	1	1	0	1	0	0
Conecuh	0	0	0	0	0	0	1	0	0
Coosa	0	0	0	0	1	0	0	0	0
Covington	0	0	0	0	0	0	1	0	0
Crenshaw	0	0	0	0	0	0	0	0	0
Cullman	0	0	0	0	0	0	0	0	0
Dale	1	2	0	0	0	0	0	1	0
Dallas	0	1	1	0	0	1	0	1	0
DeKalb	0	0	1	0	0	0	0	0	0
Elmore	0	0	3	1	0	0	1	0	0
Escambia	0	0	0	0	0	0	1	1	0
Etowah	2	0	2	1	0	0	0	1	1
Fayette	0	0	0	1	0	0	0	0	0
Franklin	0	0	0	0	0	0	0	1	0
Geneva	1	0	0	0	0	0	0	0	0
Greene	0	0	0	0	0	0	0	2	0
	0	0	0	0	0	0	-	0	0

Hale

Year to Date	P&S SYPHILIS			EARLY	LATENT S	YPHILIS	OTHER SYPHILIS			
Henry	0	0	0	0	0	0	0	0	1	
Houston	1	2	3	3	0	0	3	1	3	
Jackson	0	0	0	0	0	0	1	0	0	
Jefferson	6	17	14	4	17	13	12	21	11	
Lamar	0	0	0	0	0	0	0	0	0	
Lauderdale	1	0	0	0	0	0	1	0	0	
Lawrence	0	0	0	0	0	2	0	0	0	
Lee	0	3	3	0	1	3	0	1	0	
Limestone	0	0	0	0	0	0	0	0	0	
Lowndes	0	0	0	0	0	0	0	0	0	
Macon	0	0	1	0	0	0	0	0	0	
Madison	6	4	12	3	5	8	4	3	1	
Marengo	1	0	0	0	0	0	0	0	0	
Marion	0	0	0	0	0	0	0	0	0	
Marshall	0	0	0	0	0	1	0	0	1	
Mobile	3	1	9	3	0	1	11	6	4	
Monroe	0	0	0	1	0	0	0	0	0	
Montgomery	4	13	10	4	6	4	5	3	3	
Morgan	1	0	0	0	0	0	0	0	1	
Perry	0	0	0	0	0	0	0	0	0	
Pickens	0	0	0	0	0	0	1	0	0	
Pike	0	2	0	0	0	0	0	1	0	
Randolph	0	0	0	1	0	0	0	0	0	
Russell	0	0	2	0	0	0	1	0	0	
Shelby	1	0	1	3	2	3	0	0	1	
St Clair	0	0	0	0	0	0	2	1	0	
Sumter	0	2	0	0	0	0	0	0	0	
Talladega	1	1	1	1	1	0	1	1	0	
Tallapoosa	0	0	0	1	3	0	0	0	0	
Tuscaloosa	1	0	4	4	1	0	2	2	1	
Walker	0	0	0	0	0	1	0	0	0	
Washington	0	0	0	0	0	0	0	0	0	
Wilcox	0	0	0	0	0	0	0	2	0	
Winston	0	0	0	0	1	0	1	0	0	
Total	35	57	69	33	45	42	55	54	29	

	HI	V, NON AII	DS	HIV, S	STAGE 3 (A	AIDS)
Year to Date	2014 Jan-Mar	2015 Jan-Mar	2016 Jan-Mar	2014 Jan-Mar	2015 Jan-Mar	2016 Jan-Mar
Autuaga	0	0	—	0	0	0
Baldwin	7	0	—	0	0	—
Barbour	0	0	0	0	0	0
Bibb	0	0	0	0	0	0
Blount	0	0	0	0	0	0
Bullock	—	—	0	—	0	0
Butler	0	0	0	0	0	0
Calhoun	0	—	—	—	0	—
Chambers	—	-	0	0	0	0
Cherokee	0	0	0	0	0	0
Chilton	0	0	0	0	0	0
Choctaw	0	0	0	0	0	0
Clarke	0	0	—	0	0	0
Clay	0	0	0	0	0	0
Cleburne	0	0	0	0	0	0
Coffee	0	0	0	0	0	0
Colbert	—	0	—	0	0	0
Conecuh	0	—	—	0	0	0
Coosa	0	0	—	—	0	0
Covington	0	0	0	0	0	0
Crenshaw	0	—	0	—	0	0
Cullman	0	0	0	0	0	0
Dale	9	—	—	—	0	0
Dallas	—	—	0	0	0	0
DeKalb	—	0	0	—	0	0
Elmore	—	—	0	0	0	0
Escambia	0	0	0	0	0	0
Etowah	—	0	—	0	0	0
Fayette	0	0	0	0	0	0
Franklin	0	0	0	0	0	0
Geneva	0	0	0	0	0	0
Greene	—	0	0	0	0	0
Hale	-	0	0	0	0	0

Year to Date	HI	V, NON All	DS	HIV, STAGE 3 (AIDS)			
Henry	0	0	0	0	0	0	
Houston	0	0	_	0	0	0	
Jackson	0	0	0	0	0	0	
Jefferson	22	0	12	12	_	0	
Lamar	0	0	_	0	0	0	
Lauderdale	_	0	_	0	0	—	
Lawrence	—	0	0	0	0	0	
Lee	0	—	_	0	0	0	
Limestone	0	0	0	0	0	0	
Lowndes	0	0	0	0	0	—	
Macon	0	0	_	0	0	0	
Madison	9	0	_	—	0	0	
Marengo	0	0	0	0	0	0	
Marion	0	0	0	0	0	0	
Marshall	-	0	0	0	0	0	
Mobile	19	5	22	_	_	_	
Monroe	0	0	0	0	0	0	
Montgomery	19	7	20	7	—	—	
Morgan	—	0	0	—	0	0	
Perry	0	0	0	0	0	0	
Pickens	—	0	0	0	0	0	
Pike	0	0	0	0	0	0	
Randolph	0	0	—	0	0	0	
Russell	-	0	5	—	0	—	
Shelby	0	0	0	0	0	0	
St Clair	_	0	0	0	0	0	
Sumter	0	_	0	0	0	0	
Talladega	0	_	_	0	0	—	
Tallapoosa	0	0	0	—	0	0	
Tuscaloosa	5	0	-	—	0	0	
Walker	—	0	0	—	0	0	
Washington	0	0	0	0	0	0	
Wilcox	0	_	_	0	0	_	
Winston	0	0	0	0	0	0	
Total	115	26	87	39	4	14	

Note: 2016 cases should be interpreted with extreme caution as not all reported cases have been entered into the HIV Surveillance database. Newly diagnosed HIV, non-AIDS includes newly diagnosed HIV infections not progressing to stage 3 (AIDS) within 30 days of diagnosis. Newly diagnosed HIV, stage 3 (AIDS) includes new and preexisting infections meeting criteria for stage 3 (AIDS) infection. Data accessed April 15, 2016.

14

HELP PREVENT CONGENITAL SYPHILIS



Test at first prenatal visit



Assess sexual risk behavior during pregnancy



sexual risk behavior

assessment

Treat pregnant females in accordance with CDC

treatment guidelines



If you have any questions, contact the Alabama Department of Public Health, Division of Sexually Transmitted Disease at (334) 206-5350.

Note: Adequate treatment is defined as completion of a penicillin-based regimen, in accordance with CDC treatment guidelines, appropriate for stage of infection, initiated 30 or more days before delivery.

For pregnant women who have history of syphilis or tested positive for syphilis during pregnancy, follow up serologic titer must be monitored closely during the third trimester and repeat treatment 30 days or more before delivery.



STD PROGRAM MANAGERS BY HEALTH AREA

PHA 1 Rhonda Guthmiller 256-383-1231 Colbert CHD

PHA 2 Dana Battle 256-533-8687 Madison CHD

PHA 3 Deborah Bivins 205-562-6974 Tuscaloosa CHD **PHA 4** Lori McManus

205-930-1383

Jefferson CHD

205-685-4166

Shelby CHD

Kerry Owens

Cleburne CHD

256-463-2296 ext 1

PHA 6

Wanda McCrimon

PHA 5

PHA 7 Paul Piepho 251-580-5328 Baldwin CHD

PHA 8 Sterling Wimbish 334-293-6421 Montgomery CHD

PHA 9 Paul Piepho 251-580-5328 Baldwin CHD

PHA 10

Sterling Wimbish 334-678-5950 Houston CHD

PHA 11

Vacant 251-690-8831 Mobile CHD

